• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

princeh@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Medicine
ORCID

0000-0002-0058-2448

Prof Henry Prince

Honorary (Professorial Fellow)
Department of Medicine

884 Scholarly works
11 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma
    DOI: 10.1182/blood.2025030190
  • 2026

    Journal article

    Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
    DOI: 10.1111/imj.70329
  • 2026

    Journal article

    Cutaneous Infiltration of Waldenstrom's Macroglobulinaemia—A Two-Case Series of a Diagnostically Challenging Presentation
    DOI: 10.1111/ajd.70021
  • 2026

    Journal article

    Radiotherapy dose–response of mycosis fungoides with large cell transformation
    DOI: 10.1016/j.radonc.2025.111292
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Novel Approaches to the Treatment and Monitoring of Patients With Incurable Haematological Cancers
  • 2018

    Research Grant

    Immunobiology and Immunotherapy of Cancer
  • 2009

    Journal article

    Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
    DOI: 10.1200/JCO.2008.18.8573
Henry Prince

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Refractory coeliac disease or something else?
    DOI: 10.1016/j.pathol.2025.08.004
  • 2026

    Journal article

    Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
    DOI: 10.1080/10428194.2025.2579721
  • 2026

    Journal article

    A First-In-Human Phase 1 Study of a Novel BCMA×CD3 Bispecific T Cell Engager EMB-06 in Relapsed or Refractory Multiple Myeloma
    DOI: 10.1002/ajh.70115
  • 2026

    Journal article

    Epcoritamab for diffuse large B-cell lymphoma in a dialysis-dependent patient
    DOI: 10.1080/10428194.2026.2617970
  • 2026

    Journal article

    An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions
    DOI: 10.1080/14712598.2026.2634055
  • 2026

    Journal article

    Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
    DOI: 10.1182/blood.2025030149

RECENT PROJECTS

  • 2014

    Research Grant

    Victorian Epigenetics Group (Veg): A Collaboration for Personalised Epigenetic Cancer Therapy Through Pre-Clinical Evaluation, Novel Biomarker Development and Early Phase Clinical Trials of New Drugs.
  • 2015

    Research Grant

    Discovery of New Treatments for Therapy-Resistant Multiple Myeloma.

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224